AstraZeneca and Array BioPharma Sign Oncology Agreement
Business Review Editor
Abstract
AstraZeneca signed a licensing and collaborative agreement with Array BioPharma concerning an MEK anticancer research program. The program will include the development of Array’s lead product, ARRY-142886.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.